Allurion Announces Publication of Meta-Analysis Demonstrating the Safety and Effectiveness of the Allurion Program for Weight Loss
Allurion Technologies (NYSE: ALUR) has announced the publication of a meta-analysis demonstrating the safety and effectiveness of the Allurion Program for weight loss. The systematic review, which analyzed 11 studies involving 2,107 patients conducted between 2016 and 2024, reported an average weight reduction of 12.5% and a significant BMI reduction of 4.75 kg/m2 at four months.
The analysis also confirmed the safety of the Allurion Balloon, with a low rate of serious adverse events at just 0.90%. Additionally, the study highlighted improvements in metabolic health parameters, including HDL cholesterol, triglycerides, and glycemia. Dr. Ram Chuttani, Chief Medical Officer and Founding Partner of Allurion, emphasized that these results further support the established safety and effectiveness of the Allurion Balloon, which has been documented in 26 peer-reviewed journal articles and used to treat over 150,000 patients worldwide.
Allurion Technologies (NYSE: ALUR) ha annunciato la pubblicazione di una meta-analisi che dimostra la sicurezza e l'efficacia del Programma Allurion per la perdita di peso. La revisione sistematica, che ha analizzato 11 studi coinvolgenti 2.107 pazienti condotti tra il 2016 e il 2024, ha riportato una riduzione media del peso del 12,5% e una significativa riduzione del BMI di 4,75 kg/m2 dopo quattro mesi.
L'analisi ha inoltre confermato la sicurezza del Pallone Allurion, con una bassa percentuale di eventi avversi gravi, pari solo allo 0,90%. Inoltre, lo studio ha evidenziato miglioramenti nei parametri di salute metabolica, inclusi il colesterolo HDL, i trigliceridi e la glicemia. Il Dr. Ram Chuttani, Direttore Medico e Socio Fondatore di Allurion, ha enfatizzato che questi risultati sostengono ulteriormente la sicurezza e l'efficacia giù dimostrate del Pallone Allurion, che è stato documentato in 26 articoli di riviste scientifiche peer-reviewed e utilizzato per trattare oltre 150.000 pazienti in tutto il mondo.
Allurion Technologies (NYSE: ALUR) ha anunciado la publicación de un meta-análisis que demuestra la seguridad y efectividad del Programa Allurion para la pérdida de peso. La revisión sistemática, que analizó 11 estudios involucrando a 2.107 pacientes realizados entre 2016 y 2024, reportó una reducción media de peso del 12,5% y una reducción significativa del IMC de 4,75 kg/m2 a los cuatro meses.
El análisis también confirmó la seguridad del globo Allurion, con una baja tasa de eventos adversos graves de solo el 0,90%. Además, el estudio destacó mejoras en los parámetros de salud metabólica, incluyendo el colesterol HDL, los triglicéridos y la glucemia. El Dr. Ram Chuttani, Director Médico y Socio Fundador de Allurion, enfatizó que estos resultados respaldan aún más la seguridad y efectividad establecidas del globo Allurion, que ha sido documentado en 26 artículos de revistas revisadas por pares y utilizado para tratar a más de 150.000 pacientes en todo el mundo.
Allurion Technologies (NYSE: ALUR)은 체중 감량을 위한 Allurion 프로그램의 안전성과 효과를 입증하는 메타 분석 결과를 발표했습니다. 2016년부터 2024년까지 진행된 11개 연구를 분석한 체계적 검토에서 2,107명의 환자를 대상으로 한 결과, 평균 체중 감소 12.5%와 BMI 감소 4.75 kg/m2를 4개월 만에 보고했습니다.
분석에서는 Allurion 풍선의 안전성도 확인되었으며, 심각한 부작용 발생률이 단 0.90%로 낮다고 보고했습니다. 또한, 연구는 HDL 콜레스테롤, 중성지방 및 혈당 등 대사 건강 지표의 개선을 강조했습니다. Allurion의 최고 의료 책임자이자 창립 파트너인 Ram Chuttani 박사는 이러한 결과가 26개의 동료 검토 저널에 문서화된 Allurion 풍선의 안전성과 효과를 더욱 지지한다고 강조했습니다. 이 풍선은 전 세계에서 150,000명 이상의 환자를 치료하는 데 사용되었습니다.
Allurion Technologies (NYSE: ALUR) a annoncé la publication d'une méta-analyse démontrant la sécurité et l'efficacité du Programme Allurion pour la perte de poids. La revue systématique, qui a analysé 11 études impliquant 2 107 patients menées entre 2016 et 2024, a rapporté une réduction de poids moyenne de 12,5% et une réduction significative de l'IMC de 4,75 kg/m2 après quatre mois.
L'analyse a également confirmé la sécurité du Ballon Allurion, avec un faible taux d'événements indésirables graves de seulement 0,90%. De plus, l'étude a souligné des améliorations dans les paramètres de santé métabolique, y compris le cholestérol HDL, les triglycérides et la glycémie. Le Dr Ram Chuttani, Médecin-chef et Partenaire Fondateur d'Allurion, a souligné que ces résultats soutiennent encore plus la sécurité et l'efficacité établies du Ballon Allurion, qui a été documentée dans 26 articles de revues évaluées par des pairs et utilisé pour traiter plus de 150 000 patients à travers le monde.
Allurion Technologies (NYSE: ALUR) hat die Veröffentlichung einer Meta-Analyse bekannt gegeben, die die Sicherheit und Wirksamkeit des Allurion-Programms zur Gewichtsreduktion demonstriert. Die systematische Überprüfung, die 11 Studien mit 2.107 Patienten aus den Jahren 2016 bis 2024 analysierte, berichtete von einer durchschnittlichen Gewichtsreduktion von 12,5% und einer signifikanten BMI-Reduktion von 4,75 kg/m2 nach vier Monaten.
Die Analyse bestätigte auch die Sicherheit des Allurion-Ballons, mit einer niedrigen Rate schwerwiegender unerwünschter Ereignisse von nur 0,90%. Darüber hinaus hob die Studie Verbesserungen in den metabolischen Gesundheitsparametern hervor, einschließlich HDL-Cholesterin, Triglyceriden und Glukose. Dr. Ram Chuttani, Chief Medical Officer und Gründungspartner von Allurion, betonte, dass diese Ergebnisse die bereits etablierte Sicherheit und Wirksamkeit des Allurion-Ballons weiter unterstützen, die in 26 Fachzeitschriften dokumentiert und zur Behandlung von über 150.000 Patienten weltweit eingesetzt wurde.
- Average weight reduction of 12.5% reported in meta-analysis
- Significant BMI reduction of 4.75 kg/m2 at four months
- Low rate of serious adverse events at 0.90%
- Improvements in metabolic health parameters observed
- Over 150,000 patients treated worldwide with Allurion Balloon
- None.
Insights
This meta-analysis provides compelling evidence for the effectiveness and safety of the Allurion Program in weight loss. The study's large sample size of 2,107 patients across 11 observational studies lends credibility to its findings. Key results include:
- Average weight reduction of
12.5% - Significant BMI reduction of 4.75 kg/m2
- Low serious adverse event rate of
0.90%
These outcomes are clinically significant, especially considering the short 4-month timeframe. The improvements in metabolic health parameters (HDL cholesterol, triglycerides and glycemia) suggest broader health benefits beyond weight loss. This could position Allurion's non-invasive approach as a competitive alternative to more invasive weight loss interventions.
For investors, this data strengthens Allurion's market position and could drive increased adoption of their technology. The publication in a peer-reviewed journal adds scientific credibility, potentially influencing healthcare providers' recommendations and payer coverage decisions. However, long-term efficacy and cost-effectiveness compared to other weight loss methods will be important for sustained market growth.
Systematic review of 11 studies involving 2,107 patients reports average weight reduction of
The results of the meta-analysis demonstrated a mean weight reduction of
“The safety and effectiveness of the Allurion Balloon have been well-established in 26 peer-reviewed journal articles and with over 150,000 patients treated around the world,” said Dr. Ram Chuttani, Chief Medical Officer and Founding Partner of Allurion. "This new meta-analysis not only highlights the significant reductions in BMI and weight loss achieved by patients but also underscores the metabolic benefits of our program."
The study’s findings are further supported by the observed improvements in metabolic health parameters, particularly in HDL cholesterol, triglycerides, and glycemia, indicating the broad-reaching benefits of the Allurion Program beyond just weight reduction.
The publication can be accessed by visiting https://link.springer.com/article/10.1007/s11695-024-07453-5.
About Allurion
Allurion is dedicated to ending obesity. The Allurion Program is a weight loss platform that features the Allurion Gastric Balloon, the world’s first and only swallowable, procedure-less intragastric balloon for weight loss, and offers access to the Allurion Virtual Care Suite, including the Allurion Mobile App for consumers, Allurion Insights for health care providers featuring the Coach Iris AI Platform, and the Allurion Connected Scale. The Allurion Virtual Care Suite is also available to providers separately from the Allurion Program to help customize, monitor and manage weight loss therapy for patients regardless of their treatment plan: gastric balloon, surgical, medical or nutritional. The Allurion Gastric Balloon is an investigational device in
For more information about Allurion and the Allurion Virtual Care Suite, please visit www.allurion.com
Allurion is a trademark of Allurion Technologies, Inc. in
Forward-Looking Statements
This press release may contain certain forward-looking statements within the meaning of the
View source version on businesswire.com: https://www.businesswire.com/news/home/20241001870994/en/
Global Media
Cedric Damour
PR Manager
+33 7 84 21 02 20
cdamour@allurion.com
Investor Contact
Mike Cavanaugh, Investor Relations
ICR Westwicke
(617) 877-9641
mike.cavanaugh@westwicke.com
Source: Allurion Technologies, Inc.
FAQ
What were the key findings of the Allurion Program meta-analysis for ALUR stock?
How many patients were included in the Allurion (ALUR) meta-analysis study?
What metabolic health improvements were observed in the Allurion (ALUR) program study?
How many patients have been treated with the Allurion Balloon worldwide?
